This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-26. Anything still debated is marked as such rather than presented as settled.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
=== Cancer === While serum low 25-hydroxyvitamin D status has been associated with a higher risk of cancer in observational studies, the general conclusion is that there is insufficient evidence for an effect of vitamin D supplementation on the risk of cancer, although there is some evidence for reduction in cancer mortality.
During his 1937–1938 journey to India, Jung developed an interest in Indian philosophy and religious traditions, particularly Hinduism, Buddhism, and Advaita Vedanta, which influenced his later reflections on symbolism, the unconscious, and the concept of the Self. Jung compared Indian spiritual traditions to modern Western culture, which he described as more focused on logic and material things. He wrote that Eastern traditions preserved psychological and symbolic modes of understanding that the West had partly lost, and he expressed admiration for the philosophical depth of Indian metaphysics, yoga, and contemplative practices. At the same time, he maintained that these traditions emerged from a different cultural and psychological context, and he cautioned that their direct adoption by Westerners could be problematic without any prior psychological development through which he termed as individuation. During this visit, he declined an opportunity to meet the Advaita Vedanta sage Ramana Maharshi, for what he later explained was that he preferred to pursue insight through his own psychological work rather than through the authority of spiritual teachers. Jung discussed these thoughts in his several later writings, including Psychology and the East, The Holy Men of India, and Memories, Dreams, Reflections, where he argued that dialogue between Eastern spirituality and Western psychology could be fruitful, but that the two traditions reflected different historical paths toward understanding the human psyche and spiritual experience.
The foundation charged the new project with development, testing, licensure and mass introduction of a meningococcal conjugate vaccine. In 2002, the collaboration supported reinforced meningitis surveillance activities in 12 countries in Africa: Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Ethiopia, Ghana, Ivory Coast, Mali, Niger, Nigeria and Togo. The surveillance indicated an increased risk of outbreaks in the future and the continued need for a vaccine. MenAfriVac became available for widespread use in African meningitis belt countries in 2010. Distribution in Mali and Niger was assisted by Médecins Sans Frontières.
Sources: en.wikipedia.org
It has been argued that happiness at work is one of the driving forces behind positive outcomes at work, rather than just being a resultant product. Despite a large body of positive psychological research into the relationship between happiness and productivity, happiness at work has traditionally been seen as a potential by-product of positive outcomes at work, rather than a pathway to success in business. However a growing number of scholars, including Boehm and Lyubomirsky, argue that it should be viewed as one of the major sources of positive outcomes in the workplace.
== Tandem accelerators == Two, tandem accelerators at this facility accelerate energies up to 3 million volts (3 MeV). The function of these accelerators is to measure scarce, (cosmogenic) isotopes such as aluminium-26, beryllium-10, iodine-129 and the aforementioned carbon-14. In other words, the accelerators are used for measuring rare isotopes that are produced within earth materials, such as rocks or soil, in Earth's atmosphere, and in extraterrestrial objects such as meteorites. These are cosmogenic isotopes, produced from interaction with cosmic rays.
After 1900, once the dual nature of lichens was accepted, researchers set out to place them in a coherent taxonomic framework. For the next half-century, lichenologists treated lichens as a distinct fungal subclass—separate from other fungi yet organized by fungal traits. Alexander Zahlbruckner's monumental work epitomized this approach. Between 1907 and 1922, Zahlbruckner issued the multi-volume Catalogus Lichenum Universalis, a comprehensive catalogue and classification of every lichen then known. He first separated lichens by fungal class: the common Ascolichenes, with ascomycete hosts, and the rarer Basidiolichenes, built on basidiomycete hosts. Within Ascolichenes he next used fruiting-body form: taxa with exposed disc-like apothecia formed the Gymnocarpeae (roughly today's Lecanoromycetes), whereas those with flask-shaped, enclosed fruiting bodies became the Pyrenocarpeae (comparable to modern Ostropomycetidae). He further split these into families and suborders on spore and apothecial details—for example, Graphidineae for crustose taxa with carbonised, branching fruiting bodies (e.g., Graphis) and Cyclocarpineae for lichens bearing shield-shaped apothecia across several thallus types. Although the scheme still sat outside the broader fungal code, prioritising traits thought to track fungal evolution brought it closer to a natural system. Zahlbruckner's catalogue soon became the global standard, prized for its exhaustive synthesis even though several groupings later proved artificial. Early-20th-century schemes put the fungal partner's morphology and chemistry first.
Sources: en.wikipedia.org
The starting material was an N-substituted pyrrole derivative, which was heated to convert it by a [1,5] sigmatropic shift to the isomer with a carbon bond between the pyrrole and pyridine rings, followed by methylation and selective reduction of the pyrrole ring using tin and hydrochloric acid. Many other syntheses of nicotine, in both racemic and chiral forms have since been published.
As a result, fewer chloride ions are excreted into the bowel, decreasing the excretion of sodium ions and water, improving stool consistency and preventing diarrhea. Up to 90% of individuals living with HIV face HIV-associated diarrhea, largely caused as a side effect of antiretroviral drugs such as nucleoside analog reverse transcriptase inhibitors and protease inhibitors, which worsens with an increasingly compromised immune system. Various clinical trials have emphasized the statistically significant efficacy of crofelemer in treating HIV-associated diarrhea and the restoration of digestive regularity. In 2012, a Phase III clinical trial for diarrhea in HIV patients was completed, and the drug was approved US Food and Drug Administration (FDA) the following year under the trade name Mytesi.
=== The 1978 reconstitution === Following a number of episodes, the three 1962 representative bodies were replaced by four new associations in 1978, including the AGSI. The association moved quickly to place a pay claim, and has remained very active since. Its first general secretary was the secretary of the preceding body, Derek Nally, a sergeant from County Wexford, who was succeeded in 1983 by P.J. Rogan for a year. In 2021, two members of the National Executive raised questions about the accuracy of the AGSI accounts, and they, and then two more, resigned, and the organisation's trustees raised a formal query in their annual report. Although members of the NEC are elected from branches, the resignations were described as "human resources matters" by the AGSI president, as the association's leadership promoted constitutional changes. The accounts were signed off by the AGSI's auditors, and annual delegate conference. In 2023, during disputes with the Garda authorities over rosters for front-line Gardai, the AGSI declined to join the Garda Representative Association in their action.
Integrin alpha-11 is a protein that, in humans, is encoded by the ITGA11 gene. This gene encodes an alpha integrin. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. This protein contains an I domain, is expressed in muscle tissue, dimerizes with beta 1 integrin in vitro, and appears to bind collagen in this form. Therefore, the protein may be involved in attaching muscle tissue to the extracellular matrix. Alternative transcriptional splice variants have been found for this gene, but their biological validity is not determined. According to one study, ITGA11 expression is increased in the anterior stroma of corneal buttons excised from the eyes affected by keratoconus. Another study showed that ITGA11 is overexpressed in myofibroblasts in different human fibrotic diseases, including liver cirrhosis, renal fibrosis, and lung fibrosis tissues. ITGA11 has also been found to be upregulated in the tumor stroma of pancreatic ductal adenocarcinoma. Knocking down of ITGA11 in human pancreatic stellate cells led to the inhibition of their differentiation into myofibroblasts and paracrine effect on tumor cells.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.